Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Non-Deal Roadshow (December 2017)
23 slides from Moleculin Biotech's roadshow presentation, Dec 5, 2017
Slide 1: NDR Materials December 2017
NDR Materials NASDAQ: MBRX December 2017
Slide 2: Disclaimer
DISCLAIMER All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,”
Slide 3: Robust pipeline, blockbuster potential
3 Robust pipeline 3 distinctly different technologies, all with blockbuster potential World-leading collaboration MD Anderson Cancer Center Breakthrough disruptive technologies Annamycin for AML: non-cardiotoxic, avoids MDR1 WP1066: STAT3 inhibitor that also stimulates immune response WP1122: metabo
Slide 4: Experienced Management Team
Selected Prior Experience Walter Klemp Chairman, President & CEO Don Picker, PhD Chief Science Officer Jonathan P. Foster. CPA, CGMA EVP & CFO Robert Shepard, MD, FACP Chief Medical Officer Sandra Silberman, MD & PhD Chief Medical Officer – New Products Experienced Management Team 4
Slide 5: Science Advisory Board Members
Selected Prior Experiene Waldemar Priebe, PhD Madeleine Duvic, MD John Paul Waymack, MD, SCD Science Advisory Board Members 5
Slide 6: Development Pipeline
Development Pipeline 6 Preclinical Clinical Preparation Phase I/II Collaboration Other cancers Pancreatic Cancer Brain Tumors AML Annamycin Annamycin + WP1066 WP1066 - Glioblastoma, melanoma metastasized to the brain WP1066 - Diffuse intrinsic pontine gliomas (children) WP1220 - Cutaneous T-Cell Lym
Slide 7: Development Roadmap
7 WP1066 WP1122 Annamycin IND MDA (Clinic; adult GBM) Mayo (grant; pediatric DIPG) Other Institutions MDA SRA Avastin POC Mouse Study (Norway; GBM) WP1220 (CTCL Poland) IND/Clinic (AML) Development Roadmap CTA/Clinic (AML; Poland) Potential for other indications Mouse Study (Norway) Potential for ot
Slide 8: Value Inflection Points
Value Inflection Points Points we consider to be key development milestones that may influence big pharma’s decision to license or acquire: • Annamycin – generation of Phase I/II data consistent with the clinical trials already completed • WP1066 and WP1122 – Proof of concept (showing activity again
Slide 9: Development Strategy
Development Strategy 9 • Orphan Drug targets with high revenue potential • Focus on game-changing breakthroughs • Collaborate closely with MD Anderson Cancer Center • Minimize cash burn through virtual structure • Worldwide exclusive licenses and regulatory exclusivity create proprietary positioning
Slide 10: Industry Opportunity
Industry Opportunity 10 • Orphan Drug sales represented approximately $29 billion in revenue in 2013 • There are no approved second-line therapies for AML • CPXX sold for $1.5 billion based on improving OS by 3.5 months, yet still leaves most AML patients without hope • Similar opportunities exist i
Slide 11: Technologies developed at MD Anderson Cancer Center
Most of our technologies were developed at MD Anderson Cancer Center, the world’s largest cancer research facility centered within the world’s largest medical center With over 1,500 cancer researchers, our sponsored research has been supported by truly state of the art resources 11
Slide 12: Delivering Solutions
Delivering Solutions 12
Slide 13: Annamycin Critical Advantages over Leading Drug
Annamycin Critical Advantages over Leading Drug Leading drugs are cardiotoxic and lose efficacy due to multidrug resistance Annamycin has little to no cardiotoxicity, avoids multidrug resistance, has been shown to be more potent in AML cell lines and has shown activity in patients who failed standar
Slide 14: Annamycin Delivers Remarkable Performance
Annamycin Delivers Remarkable Performance In a proof-of-concept Phase I/II clinical trial, Annamycin was given to patients who had failed an average of five previous induction therapy attempts 37% of those patients cleared enough of their leukemic cells to qualify for a bone marrow transplant We bel
Slide 15: Leukemia and bone marrow transplant limitations
20% 80% Induction Therapy (Qualify for BMT) Success Failure 80 % 20 % BMT (Results in Cure) Leukemia is a cancer of the white blood cells and the acute forms of leukemia can manifest quickly and leave patients with limited treatment options The only viable option for acute leukemia patients is a bon
Slide 16: WP1066 Portfolio Overview
WP1066 Portfolio Overview Based On Natural Compound Built from chemical backbone of bee pollen compound Unique Dual Action First drug to both directly inhibit tumor signaling while also stimulating patient immune response Activity Against Hardest-to-Treat Cancers Pre-clinical testing shows high leve
Slide 17: Proposed MOA of WP1066
Proposed MOA of WP1066: Deubiquitinase-Mediated Control of p-STAT3 17 Proteasome Proteasomal Degradation p-STAT3, an activated form of STAT3 Ubiquitinated STAT3 Activated STAT3 (p-STAT3) relies on deubiquitinating enzymes (DUBs) to reverse ubiquitination and decrease proteasomal hydrolysis WP1066 in
Slide 18: WP1122 Portfolio Overview
WP1122 Portfolio Overview Tumor cell Normal cell Addicted to Sugar A brain tumor requires as much as 18 to 37 times as much glucose to survive as a healthy brain cell Starving a Tumor to Death This eventually led to the theory that, if we feed tumor cells a glucose decoy (one that can’t convert into
Slide 19: WP1122 is Effective In Vivo against Gliomas
WP1122 is Effective In Vivo against Gliomas 19 Orthotopic Glioblastoma Model in Mice WP1122 used alone has at least the same or greater activity than temozolomide (Temodar®), a current standard of care in patients diagnosed with glioblastoma 0 2 4 6 8 10 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Slide 20: Recent Developments
Recent Developments FDA Approved IND for Annamycin clinical trials (as well as Orphan Drug designation) Submitted request for CTA in Poland for Annamycin clinical trial FDA Approved Clinician-sponsored IND for WP1066 by MD Anderson Potential Mayo Clinic Study for WP1066 for Pediatric Brain Tumors An
Slide 21: Financial Overview
ae a Financial Overview
Slide 22: Financial Statement Summary
Financial Statement Summary The above unaudited financial information should be read with the notes, the financial statements of Moleculin and the notes thereto which are included its filings with the SEC. 22 In thousands - except for loss per share and shares outstanding For the Nine Months Ended S
Slide 23: Robust pipeline, blockbuster potential
23 Robust pipeline 3 distinctly different technologies, all with blockbuster potential World-leading collaboration MD Anderson Cancer Center Breakthrough disruptive technologies Annamycin for AML: non-cardiotoxic, avoids MDR1 WP1066: STAT3 inhibitor that also stimulates immune response WP1122: metab
Moleculin Biotech — Non-Deal Roadshow (December 2017) on 6ix